Medigene AG (FRA:MDG1) is a biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
MediGene AG
FRA:MDG1 ISIN:DE000A161NA3
News
Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
###
13,356 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 21) (Last 30 Days: 98) (Since Published: 8837)